Clovis Oncology discontinue phase 2 bladder cancer trial
April 15, 2019Sales and Marketing Cancer, Clovis Oncology, US, bladder cancer, metastatic bladder cancer
Colorado-based pharma firm Clovis Oncology has said in a filing to the US Securities and Exchange Commission that it is …
Bayer VP elected to two of the firm’s executive committees
April 12, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Bayer, appointment
Dr Monika Lessl has been appointed to Bayer Foundations’ executive committee, selected by the German pharmaceutical firm’s Board of Management …
Daiichi Sankyo name current COO Sunao Manabe as firm’s new CEO
April 12, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing
Daiichi Sankyo have said Sunao Manabe, the company’s current COO will take over from George Nakayama as the firm’s new …
GW Pharma announce Darren Cline as company’s new Chief Commercial Officer
April 12, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing
GW Pharmaceuticals have announced the appointment of Darren Cline as the company’s new US Chief Commercial Officer. Cline will lead …
FDA expands Keytruda label to include stage 3 and 4 non-small cell lung cancer
April 12, 2019Medical Communications, Research and Development Cancer, MSD, keytruda, lung cancer, non-small cell lung cancer, pharma
MSD has revealed that its anti-PD-1 therapy Keytruda (pembrolizumab) has received expanded indication from the FDA to include the first-line …
Janssen’s Symtuza around 90% effective in achieving undetectable HIV-1 viral loads, when used immediately following diagnosis
April 12, 2019Medical Communications HIV, Janssen, Symtuza, pharma
Janssen has lifted the curtain on data from the first Phase 3 trial investigating the efficacy of Symtuza (darunavir 800mg, …
Top Ten most popular articles on Pharmafile.com this week!
April 12, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Astellas, BMS, Eisai, Gilead, MSD, Pfizer, ViiV, indivior
This week was an excellent week for recommendations and approvals after Eisai, MSD, Pfizer, BMS and ViiV scored wins. Meanwhile …
Throat lozenges could be contributing to antimicrobial resistance
April 12, 2019Medical Communications AMR, Antibiotics, OTC, WHO, antimicrobial, health
Over the counter (OTC) throat lozenges could be contributing to antimicrobial resistance (AMR) according to research presented at this year’s …
Opioid crisis cost US government nearly $38 billion in lost taxes
April 11, 2019Medical Communications, Research and Development US, government, opioid crisis, opioids, public health, tax revenue
The opioid epidemic may have cost US state and federal governments as much as $37.8 billion in lost tax revenue, …
Traffic pollution linked to four million childhood asthma cases each year
April 11, 2019Research and Development Air pollution, NO2, Traffic, asthma, emissions, pollution, public health
Air pollution is linked to four million cases of childhood asthma each year, according to research published in The Lancet …
Living with a rare chromosome disorder
April 11, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Inv Dup Del 8p, feature, patient experience, pharma
Rebecca Pender’s daughter Hannah lives with the ultra-rare condition Inv Dup Del 8p, a genetic arrangement that affects just 80 …
Reckitt Benckiser to unveil £105 R&D site in Hull by end of June
April 11, 2019Manufacturing and Production Hull, R&D, Reckitt Benckiser, UK, pharma
Reckitt Benckiser (RB) has announced that its £105 million research and development facility in the UK city of Hull – …
Researchers use CRISPR to reveal gene targets in 30 types of cancer
April 11, 2019Research and Development Cancer, crispr, drug development, genes, genetics, oncology
Researchers at the Wellcome Sanger Institute and Open Targets have been able to identify thousands of genes which play a …
Novartis’ Kisqali combo rejected by NICE for advanced breast cancer
April 11, 2019Sales and Marketing Kisqali, NHS, NICE, Novartis, pharma
Novartis’ Kisqali (ribociclib) has been rejected for use on the NHS by NICE for the treatment of advanced breast cancer, …
Gilead to lay off one fifth of sales force
April 11, 2019Sales and Marketing Gilead, Jobs, Letairis, Ranexa, redundancy, sales
Gilead Sciences is preparing to lay off around a fifth of its salesforce in anticipation for the expiry of patents …
FDA green lights Amgen and UCB’s Evenity in postmenopausal osteoporosis patients
April 10, 2019Research and Development, Sales and Marketing Amgen, Evenity, FDA, UCB Pharma, osteoporosis, pharma
The FDA has decided to approve Amgen and UCB Pharma’s Evenity (romosozumab-aqqg) for the treatment of postmenopausal osteoporosis patients at …
Indivior shares fall by 70% after allegations of fraud
April 10, 2019Research and Development Virginia, indivior, opioid crisis, opioids, suboxone
Shares in London-listed Indivior plummeted this morning after US Federal prosecutors said the British drugmaker had deceived doctors as to …
Europe approves Lynparza in HER2-, gBRCAm advanced breast cancer
April 10, 2019Research and Development, Sales and Marketing AstraZeneca, Cancer, MSD, breast cancer, lynparza, pharma
Lynparza (olparib), the poly ADP ribose polymerase (PARP) inhibitor developed by AstraZeneca and MSD, has been awarded marketing approval by …
New Yorkers must be vaccinated or face a fine
April 10, 2019Research and Development Brooklyn, New York, infectious diseases, measles, public health, vaccines
A public health emergency has been declared in New York following an outbreak of measles. Residents of certain postcodes in …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
